{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:26:58Z","timestamp":1784698018641,"version":"3.55.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007607","name":"University Research Council, Aga Khan University","doi-asserted-by":"publisher","award":["183027SUR"],"award-info":[{"award-number":["183027SUR"]}],"id":[{"id":"10.13039\/100007607","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15057-0","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T14:14:20Z","timestamp":1762524860000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["TP53 c.730G\u2009&gt;\u2009A pathogenic variant as a plausible candidate biomarker in pancreatic ductal adenocarcinoma patients from Karachi, pakistan: a retrospective cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"SM Adnan","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumna","family":"Adnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleema Mehboob","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zubair","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iqbal","family":"Azam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabish","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasnain Ahmed","family":"Farooqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"15057_CR1","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(4):251\u2013274.","DOI":"10.3322\/caac.21834"},{"key":"15057_CR2","unstructured":"Surveillance, Epidemiology, and End Results (SEER) database, USA 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html. Accessed on 30 April 2024.\u00a0"},{"issue":"4","key":"15057_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance Olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317\u201327.","journal-title":"N Engl J Med"},{"key":"15057_CR4","unstructured":"Food Drugs Administration (FDA) USA. 2024.\u00a0https:\/\/www.fda.gov. Accessed on 30 April 2024.\u00a0"},{"issue":"9","key":"15057_CR5","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/cncy.22589","volume":"130","author":"D Razzano","year":"2022","unstructured":"Razzano D, Bouza SJ, Hernandez PV, Wang M, Robert ME, Walther Z, et al. Comprehensive molecular profiling of pancreatic ductal adenocarcinoma in FNA, biopsy, and resection specimens. Cancer Cytopathol. 2022;130(9):726\u201334.","journal-title":"Cancer Cytopathol"},{"issue":"1","key":"15057_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/17425255.2023.2178895","volume":"19","author":"M Biswas","year":"2023","unstructured":"Biswas M, Jinda P, Sukasem C. Pharmacogenomics in asians: differences and similarities with other human populations. Expert Opin Drug Metab Toxicol. 2023;19(1):27\u201341.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"15057_CR7","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41591-022-01738-x","volume":"28","author":"CS Pramesh","year":"2022","unstructured":"Pramesh CS, Badwe RA, Bhoo-Pathy N, Booth CM, Chinnaswamy G, Dare AJ, et al. Priorities for cancer research in low-and middle-income countries: a global perspective. Nat Med. 2022;28(4):649\u201357.","journal-title":"Nat Med"},{"issue":"1","key":"15057_CR8","doi-asserted-by":"publisher","first-page":"1781333","DOI":"10.1080\/2162402X.2020.1781333","volume":"9","author":"L Peng","year":"2020","unstructured":"Peng L, Qin BD, Xiao K, Xu S, Yang JS, Zang YS, et al. A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy. Oncoimmunology. 2020;9(1):1781333.","journal-title":"Oncoimmunology"},{"key":"15057_CR9","doi-asserted-by":"publisher","first-page":"678705","DOI":"10.3389\/fonc.2021.678705","volume":"11","author":"S Ajaz","year":"2021","unstructured":"Ajaz S, Zaidi SE, Ali SM, Siddiqa A, Memon MA, Firasat S, et al. Absence of glutathione S-transferase theta 1 gene is significantly associated with breast cancer susceptibility in Pakistani population and poor overall survival in breast cancer patients: A case-control and case series analysis. Front Oncol. 2021;11:678705.","journal-title":"Front Oncol"},{"issue":"2","key":"15057_CR10","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s11033-021-06964-z","volume":"49","author":"SM Ali","year":"2022","unstructured":"Ali SM, Adnan Y, Ahmad Z, Farooqui HA, Chawla T, Ali SA. Genetic landscape of pancreatic adenocarcinoma patients: a pilot study from Pakistan. Mol Biol Rep. 2022;49(2):1341\u201350.","journal-title":"Mol Biol Rep"},{"issue":"3","key":"15057_CR11","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3390\/cancers15030779","volume":"15","author":"J Liu","year":"2023","unstructured":"Liu J, Mroczek M, Mach A, St\u0119pie\u0144 M, Aplas A, Pronobis-Szczylik B, et al. Genetics, genomics and emerging molecular therapies of pancreatic cancer. Cancers. 2023;15(3):779.","journal-title":"Cancers"},{"issue":"1","key":"15057_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13045-022-01375-4","volume":"15","author":"K Parikh","year":"2022","unstructured":"Parikh K, Banna G, Liu SV, Friedlaender A, Desai A, Subbiah V, Addeo A. Drugging KRAS: current perspectives and state-of-art review. J Hematol Oncol. 2022;15(1):152.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"15057_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang H, Guo M, Wei H, Chen Y. Targeting p53 pathways: Mechanisms, structures and advances in therapy. Sig Transduct Target Ther. 2023;8(1):92.","journal-title":"Sig Transduct Target Ther"},{"issue":"3","key":"15057_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3390\/ph17030333","volume":"17","author":"T Ismail","year":"2024","unstructured":"Ismail T, Alzneika S, Riguene E, Al-Maraghi S, Alabdulrazzak A, Al-Khal N, et al. BRCA1 and its vulnerable C-Terminal BRCT domain: Structure, function, genetic mutations and links to diagnosis and treatment of breast and ovarian cancer. Pharmaceut. 2024;17(3):333.","journal-title":"Pharmaceut"},{"issue":"1","key":"15057_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00018-023-05068-0","volume":"81","author":"D Zhang","year":"2024","unstructured":"Zhang D, Ni QQ, Wang SY, He WF, Hong ZX, Liu HY, et al. APC mutations disrupt \u03b2-catenin destruction complex condensates organized by Axin phase separation. Cell Mol Life Sci. 2024;81(1):57.","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"15057_CR16","first-page":"378","volume":"40","author":"P Carotenuto","year":"2012","unstructured":"Carotenuto P, Roma C, Cozzolino S, Fenizia F, Rachiglio AM, Tatangelo F, et al. Detection of KRAS variants in colorectal cancer with fast COLD-PCR. Int J Oncol. 2012;40(2):378\u201384.","journal-title":"Int J Oncol"},{"issue":"5","key":"15057_CR17","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1515\/tjb-2019-0137","volume":"45","author":"E Dirican","year":"2020","unstructured":"Dirican E, Erbarut Seven \u0130, Kaya H, U\u011furlu M\u00dc, Peker \u0130, G\u00fcll\u00fco\u011flu BM, \u00d6zer A, Akkiprik M. PIK3CA and TP53 variants and SALL4, PTEN and PIK3R1 gene expression levels in breast cancer. Turk J Biochem. 2020;45(5):515\u201323.","journal-title":"Turk J Biochem"},{"key":"15057_CR18","unstructured":"Agenbag G. Molecular genetic analysis of familial breast cancer in South Africa (Doctoral dissertation, Stellenbosch: University of Stellenbosch). 2005.https:\/\/core.ac.uk\/download\/pdf\/37319812.pdf. Accessed on 22 September 2025."},{"issue":"3","key":"15057_CR19","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/0092-8674(81)90021-0","volume":"66","author":"J Groden","year":"1991","unstructured":"Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, et al. Identification and characterization of the Familial adenomatous polyposis coli gene. Cell. 1991;66(3):589\u2013600.","journal-title":"Cell"},{"issue":"3","key":"15057_CR20","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0006-291X(05)80032-4","volume":"184","author":"A Stella","year":"1992","unstructured":"Stella A, Lonoce A, Resta N, Gentile M, Susca F, Mareni C, et al. Familial adenomatous polyposis: identification of a new frameshift variant of the APC gene in an Italian family. Biochem Biophys Res Commun. 1992;184(3):1357\u201363.","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"15057_CR21","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.3390\/jpm12101746","volume":"12","author":"C Nero","year":"2022","unstructured":"Nero C, Duranti S, Giacomini F, Minucci A, Giac\u00f2 L, Piermattei A, et al. Integrating a comprehensive cancer genome profiling into clinical practice: a blueprint in an Italian referral center. J Pers Med. 2022;12(10):1746.","journal-title":"J Pers Med"},{"issue":"12","key":"15057_CR22","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.3390\/cancers15123231","volume":"15","author":"TZ Liang","year":"2023","unstructured":"Liang TZ, Katz MH, Prakash LR, Chatterjee D, Wang H, Kim M, et al. Comparative analyses of the clinicopathologic features of Short-Term and Long-Term survivors of patients with pancreatic ductal adenocarcinoma who received neoadjuvant therapy and pancreatoduodenectomy. Cancers. 2023;15(12):3231.","journal-title":"Cancers"},{"issue":"3","key":"15057_CR23","doi-asserted-by":"publisher","first-page":"745","DOI":"10.4103\/jcrt.jcrt_1778_21","volume":"19","author":"MM Eddfair","year":"2023","unstructured":"Eddfair MM, Abdulrahman O, Alqawi O, Assidi M, Buhmeida A, Elturki A, et al. Correlations of demographical and clinicopathological features with patient outcome of pancreatic ductal adenocarcinoma: A retrospective study (2010\u20132018) from a Libyan cohort. J Cancer Res Ther. 2023;19(3):745\u201352.","journal-title":"J Cancer Res Ther"},{"key":"15057_CR24","doi-asserted-by":"crossref","unstructured":"Muchiri SW, Ogutu EO, Oyiro PO, Aabakken L. Clinicopathologic characteristics and treatment outcomes of pancreatic cancer patients at a tertiary referral hospital in Kenya. Ecancermedicalscience. 2024;18","DOI":"10.3332\/ecancer.2024.1682"},{"issue":"12","key":"15057_CR25","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.hpb.2022.09.003","volume":"24","author":"N Muhammad","year":"2022","unstructured":"Muhammad N, Sadaqat R, Naeemi H, Masood I, Hassan U, Ijaz B, et al. Contribution of germline PALB2 variants to an unselected and prospectively registered pancreatic cancer patient cohort in Pakistan. HPB. 2022;24(12):2134\u201344.","journal-title":"HPB"},{"issue":"1","key":"15057_CR26","first-page":"22","volume":"21","author":"N Muhammad","year":"2023","unstructured":"Muhammad N, Azeem A, Arif S, Naeemi H, Masood I, Hassan U, et al. Prevalence of BRCA1 and BRCA2 germline variants in an unselected pancreatic cancer patient cohort in Pakistan. HCCP. 2023;21(1):22.","journal-title":"HCCP"},{"issue":"3","key":"15057_CR27","first-page":"228","volume":"104","author":"NT Ihle","year":"2012","unstructured":"Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. JCNI. 2012;104(3):228\u201339.","journal-title":"JCNI"},{"key":"15057_CR28","doi-asserted-by":"crossref","unstructured":"Duldulao MP, Lee W, Nelson RA, Li W, Chen Z, Kim J, Garcia-Aguilar J. Variants in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma. Ann Surg Oncol. 2013;20(7):2166\u201371.","DOI":"10.1245\/s10434-013-2910-0"},{"issue":"20","key":"15057_CR29","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.3390\/cancers15205015","volume":"15","author":"VH de Jesus","year":"2023","unstructured":"de Jesus VH, Mathias-Machado MC, de Farias JP, Aruquipa MP, J\u00e1come AA, Peixoto RD. Targeting KRAS in pancreatic ductal adenocarcinoma: the long road to cure. Cancers. 2023;15(20):5015.","journal-title":"Cancers"},{"issue":"21","key":"15057_CR30","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.3390\/cancers14215430","volume":"14","author":"P Cascetta","year":"2022","unstructured":"Cascetta P, Marinello A, Lazzari C, Gregorc V, Planchard D, Bianco R, et al. KRAS in NSCLC: state of the Art and future perspectives. Cancers. 2022;14(21):5430.","journal-title":"Cancers"},{"key":"15057_CR31","doi-asserted-by":"crossref","unstructured":"Zeissig MN, Ashwood LM, Kondrashova O, Sutherland KD. Next batter up! Targeting cancers with KRAS-G12D variants. Trends Cancer. 2023;9(11):955-67.","DOI":"10.1016\/j.trecan.2023.07.010"},{"issue":"14","key":"15057_CR32","doi-asserted-by":"publisher","first-page":"5600","DOI":"10.3390\/molecules28145600","volume":"28","author":"E Miyamoto-Sato","year":"2023","unstructured":"Miyamoto-Sato E, Imanishi S, Huang L, Itakura S, Iwasaki Y, Ishizaka M. A First-Class degrader candidate targeting both KRAS G12D and G12V mediated by CANDDY technology independent of ubiquitination. Molecules. 2023;28(14):5600.","journal-title":"Molecules"},{"key":"15057_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.canlet.2019.05.037","volume":"459","author":"N Awasthi","year":"2019","unstructured":"Awasthi N, Kronenberger D, Stefaniak A, Hassan MS, von Holzen U, Schwarz MA, Schwarz RE. Dual Inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel\/gemcitabine chemotherapy response in preclinical models of pancreatic cancer. Cancer Lett. 2019;459:41\u20139.","journal-title":"Cancer Lett"},{"issue":"5","key":"15057_CR34","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/s41418-022-00980-7","volume":"29","author":"D Hoyos","year":"2022","unstructured":"Hoyos D, Greenbaum B, Levine AJ. The genotypes and phenotypes of missense variants in the proline domain of the p53 protein. Cell Death Differ. 2022;29(5):938\u201345.","journal-title":"Cell Death Differ"},{"key":"15057_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12881-015-0169-y","volume":"16","author":"SL Arcand","year":"2015","unstructured":"Arcand SL, Akbari MR, Mes-Masson AM, Provencher D, Foulkes WD, Narod SA, Tonin PN. Germline TP53 mutational spectrum in French Canadians with breast cancer. BMC Med Genet. 2015;16:1\u20131.","journal-title":"BMC Med Genet"},{"issue":"1","key":"15057_CR36","doi-asserted-by":"publisher","first-page":"20221","DOI":"10.1038\/srep20221","volume":"6","author":"H Hu","year":"2016","unstructured":"Hu H, Liu J, Liao X, Zhang S, Li H, Lu R, et al. Genetic and functional analysis of a Li fraumeni syndrome family in China. Sci Rep. 2016;6(1):20221.","journal-title":"Sci Rep"},{"issue":"5","key":"15057_CR37","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3747\/co.22.2588","volume":"22","author":"A Schiavi","year":"2015","unstructured":"Schiavi A, Lavigne J, Turcotte R, Kasprzak L, Dumas N, Chong G, et al. Using a family history questionnaire to identify adult patients with increased genetic risk for sarcoma. Curr Oncol. 2015;22(5):317\u201325.","journal-title":"Curr Oncol"},{"key":"15057_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12957-019-1741-2","volume":"17","author":"N Batta","year":"2019","unstructured":"Batta N, Pandey M. Mutational spectrum of tobacco associated oral squamous carcinoma and its therapeutic significance. World J Surg Oncol. 2019;17:1\u20132.","journal-title":"World J Surg Oncol"},{"issue":"3","key":"15057_CR39","doi-asserted-by":"publisher","first-page":"315","DOI":"10.14701\/ahbps.2021.25.3.315","volume":"25","author":"IA Voutsadakis","year":"2021","unstructured":"Voutsadakis IA. Variants of p53 associated with pancreatic cancer and therapeutic implications. Ann Hepato-biliary-pancreat Surg. 2021;25(3):315.","journal-title":"Ann Hepato-biliary-pancreat Surg"},{"issue":"1","key":"15057_CR40","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3934\/mbe.2022010","volume":"19","author":"Y Liu","year":"2022","unstructured":"Liu Y, Cheng L, Song X, Li C, Zhang J, Wang L. A TP53-associated immune prognostic signature for the prediction of the overall survival and therapeutic responses in pancreatic cancer. Math Biosci Eng. 2022;19(1):191\u2013208.","journal-title":"Math Biosci Eng"},{"key":"15057_CR41","doi-asserted-by":"crossref","unstructured":"Calheiros J, Corbo V, Saraiva L. Overcoming therapeutic resistance in pancreatic cancer: emerging opportunities by targeting BRCAs and p53. BBA-REV Cancer. 2023;1878(4):188914.","DOI":"10.1016\/j.bbcan.2023.188914"},{"issue":"1","key":"15057_CR42","first-page":"1076","volume":"4","author":"AS Biswas","year":"2017","unstructured":"Biswas AS, Chakraborty A. BRCA1 and BRCA2 variant in pancreatic cancer: significance in therapeutic approach. Austin J Gastroenterol. 2017;4(1):1076.","journal-title":"Austin J Gastroenterol"},{"key":"15057_CR43","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3389\/fgene.2018.00378","volume":"9","author":"R Zuntini","year":"2018","unstructured":"Zuntini R, Ferrari S, Bonora E, Buscherini F, Bertonazzi B, Grippa M, et al. Dealing with BRCA1\/2 unclassified variants in a cancer genetics clinic: does cosegregation analysis help? Front Genet. 2018;9:378.","journal-title":"Front Genet"},{"issue":"17","key":"15057_CR44","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-20-0255","volume":"26","author":"P Bouwman","year":"2020","unstructured":"Bouwman P, van der Heijden I, van der Gulden H, de Bruijn R, Braspenning ME, Moghadasi S, et al. Functional categorization of BRCA1 variants of uncertain clinical significance in homologous recombination repair complementation assays. Clin Cancer Res. 2020;26(17):4559\u201368.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"15057_CR45","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.ajhg.2021.09.003","volume":"108","author":"SM Caputo","year":"2021","unstructured":"Caputo SM, Golmard L, L\u00e9one M, Damiola F, Guillaud-Bataille M, Revillion F, et al. Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach. AJHG. 2021;108(10):1907\u201323.","journal-title":"AJHG"},{"key":"15057_CR46","doi-asserted-by":"crossref","unstructured":"Stella S, Vitale SR, Martorana F, Massimino M, Pavone G, Lanzafame K, et al. Mutational analysis of BRCA1 and BRCA2 genes in breast cancer patients from Eastern Sicily. Cancer Manag Res. 2022;14:1341\u201352.","DOI":"10.2147\/CMAR.S348529"},{"key":"15057_CR47","unstructured":"ClinVar Database, National Center for Biotechnology Information (NCBI) . USA, 2024. https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/variation\/37679\/. Accessed on\u00a030 April 2024.\u00a0"},{"issue":"19","key":"15057_CR48","doi-asserted-by":"publisher","first-page":"5092","DOI":"10.1158\/1078-0432.CCR-20-1301","volume":"26","author":"MJ Pishvaian","year":"2020","unstructured":"Pishvaian MJ, Wang H, He AR, Hwang JJ, Smaglo BG, Kim SS, et al. A phase I\/II study of veliparib (ABT-888) in combination with 5-fluorouracil and oxaliplatin in patients with metastatic pancreatic cancer. Clin Cancer Res. 2020;26(19):5092\u2013101.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"15057_CR49","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.3748\/wjg.v27.i17.1943","volume":"27","author":"MN Rosen","year":"2021","unstructured":"Rosen MN, Goodwin RA, Vickers MM. BRCA mutated pancreatic cancer: A change is coming. World J Gastroenterol. 2021;27(17):1943.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"15057_CR50","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.mpdhp.2015.04.005","volume":"21","author":"CE Hagen","year":"2015","unstructured":"Hagen CE, Setia N, Lauwers GY. Familial adenomatous polyposis: a review of Gastrointestinal manifestations. Diagn Histopathol. 2015;21(4):152\u201360.","journal-title":"Diagn Histopathol"},{"issue":"9","key":"15057_CR51","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3390\/cells8091084","volume":"8","author":"JM Cole","year":"2019","unstructured":"Cole JM, Simmons K, Prosperi JR. Effect of adenomatous polyposis coli loss on tumorigenic potential in pancreatic ductal adenocarcinoma. Cells. 2019;8(9):1084.","journal-title":"Cells"},{"key":"15057_CR52","unstructured":"Ghorban Oghli Z. Genetic and clinical aspects of inherited syndromes associated with adenomatous polyposis (Doctoral dissertation, Leiden University). 2023.\u00a0https:\/\/scholarlypublications.universiteitleiden.nl\/handle\/1887\/3618966. Accessed on 22 September 2025."},{"issue":"6","key":"15057_CR53","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/gcc.2870030609","volume":"3","author":"WL Neuman","year":"1991","unstructured":"Neuman WL, Wasylyshyn ML, Jacoby R, Erroi F, Angriman I, Montag A, et al. Evidence for a common molecular pathogenesis in colorectal, gastric, and pancreatic cancer. Genes Chromosomes Cancer. 1991;3(6):468\u201373.","journal-title":"Genes Chromosomes Cancer"},{"issue":"23","key":"15057_CR54","first-page":"6696","volume":"52","author":"A Horii","year":"1992","unstructured":"Horii A, Nakatsuru S, Miyoshi Y, Ichii S, Nagase H, Ando H, et al. Frequent somatic variants of the APC gene in human pancreatic cancer. Cancer Res. 1992;52(23):6696\u20138.","journal-title":"Cancer Res"},{"issue":"6","key":"15057_CR55","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/bjc.1992.173","volume":"65","author":"SF Ding","year":"1992","unstructured":"Ding SF, Habib NA, Delhanty JD, Bowles L, Greco L, Wood C, et al. Loss of heterozygosity on chromosomes 1 and 11 in carcinoma of the pancreas. Br J Cancer. 1992;65(6):809\u201312.","journal-title":"Br J Cancer"},{"issue":"1","key":"15057_CR56","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41392-021-00701-5","volume":"6","author":"F Yu","year":"2021","unstructured":"Yu F, Yu C, Li F, Zuo Y, Wang Y, Yao L, et al. Wnt\/\u03b2-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther. 2021;6(1):307.","journal-title":"Signal Transduct Target Ther"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15057-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15057-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15057-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:05:42Z","timestamp":1762527942000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15057-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15057"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15057-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Ethical Review Committee of Aga Khan University Hospital, Karachi, Pakistan (2018-0449-1058). Written informed consent was obtained from all the participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of their data with anonymous identities.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1730"}}